Skip to content

Clinical study of an Ayurveda formulation containing Gold and Indian Gooseberry along with Tulasi juice as an add on therapy in standard care of COVID 19 patients

Study of Swarna Amalaki as an immunomodulator in Covid-19 Patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/10/028414
Enrollment
60
Registered
2020-10-15
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Swarna Amalaki as an adjuvant therapy: Swarna Amalaki as an adjuvant therapy to standard management of COVID-19 containing Swarna Bhasma- 30mg/day and Amalaki Churna ââ?¬â?? 3gms/day t

Sponsors

Ministry of AYUSH New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed patients of COVID 19with positive RT-PCR test of either sex, between the age group of 20 -70 years 2. Patients of COVID 19 receiving standard treatment protocol as prescribed by ICMR/MOHFW, Govt. of India 3. Patients giving informed consent

Exclusion criteria

Exclusion criteria: 1. COVID 19 patients requiring ventilator support 2. Pregnant ladies and children 3. COVID 19 patients with other severe, unstable, uncontrolled co-morbid medical illness such as Diabetes, Hypertension, Cardiac disorders, liver, kidney disorders and lung disorders or other diseases of concern which may put the patient in risk during the study

Design outcomes

Primary

MeasureTime frame
Early recovery from clinical signs and symptoms such as cough, cold, fever and associated symptoms of COVID 19 without further complications Negative result for COVID 19 testTimepoint: Baseline,Day7,14,21and 28

Secondary

MeasureTime frame
Positive immunomodulation as judged by modification of immunological parameters - IgG, IgM values,CD4 and CD8 cell counts, Absolute Lymphocyte countTimepoint: Baseline and Day 28

Countries

India

Contacts

Public ContactJyothy K B

Department of Kaumarabhritya

jyothy.kb@dmimsu.edu.in07776014076

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026